Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies

Published 2016 View Full Article

Authors

Keywords

SGLT2 Inhibitors, Dapagliflozin, Canagliflozin, Empagliflozin, CANVAS, CREDENCE, DECLARE-TIMI 58, Cardiovascular outcomes, Nonglycemic benefit of SGLT2 inhibitors

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY

Volume 212, Issue -, Pages 29-36

Publisher

Elsevier BV

Online

2016-03-10

DOI

10.1016/j.ijcard.2016.02.134

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started